文献速递哮喘

最佳哮喘控制:是时候设定新目标了

Optimal Asthma Control: Time for a New Target.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

本综述指出成人哮喘阶梯治疗中,良好控制仅约70%患者可达,且需将吸入糖皮质激素/长效β2受体激动剂增至维持剂量相当于每日口服泼尼松5mg的系统副作用水平。文章还讨论了共存疾病、患者感知与指南评估差异及症状控制与急性发作风险的不对等,建议研究最佳控制水平和不同治疗目标的价值。

要点

  • 成人哮喘良好控制仅约70%可达,需权衡吸入激素剂量与系统副作用。
  • 共存疾病和生活方式因素可影响哮喘控制,需针对性管理。
  • 症状控制不等同于消除急性发作风险,尤其重症哮喘。

核心结论

  • 成人哮喘良好控制仅约70%患者可达,需将吸入糖皮质激素/长效β2受体激动剂增至维持剂量相当于每日口服泼尼松5mg的系统副作用水平。
  • 症状控制不等同于消除急性发作风险,尤其重症哮喘患者。
  • 建议进一步研究最佳哮喘控制水平和不同治疗目标(如2型气道炎症控制)的价值。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 成人哮喘良好控制仅约70%患者可达,需将吸入糖皮质激素/长效β2受体激动剂增至维持剂量相当于每日口服泼尼松5mg的系统副作用水平。
  • 部分控制哮喘与接近最大水平的生活质量相关,损伤最小,可解释患者感知与指南评估的差异。
  • 症状控制不等同于消除急性发作风险,尤其重症哮喘患者。

关键数值与推荐

  • 维持吸入糖皮质激素剂量相当于每日口服泼尼松5mg的系统副作用水平。

临床怎么用

  • 成人哮喘阶梯治疗中需权衡吸入激素剂量增加与系统副作用。
  • 评估哮喘控制时应考虑共存疾病和生活方式因素。
  • 不应将症状控制简单等同于急性发作风险消除。

局限性

  • 为综述,未报告系统检索策略与纳入研究特征。
  • 未提供具体研究数据或样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The stepwise approach to pharmacological treatment in adult asthma mandates that asthma treatment is progressively stepped up to achieve symptom control and reduce the risk of exacerbations and stepped down after a period of prolonged control. This review proposes that in adults without good asthma control, well-controlled asthma can only be achieved in approximately 70% of patients across the strata of severity, and only if there is a progressive increase in inhaled corticosteroid/long-acting β2 agonist therapy to a maintenance inhaled corticosteroid dose that causes the same magnitude of systemic side effects as oral prednisone at a 5-mg daily dose. Another consideration is that in a person with asthma, there are numerous overlapping disorders that can present with symptoms indistinguishable from asthma, comorbidities that contribute to poor control and lifestyle/environmental factors that require treatment in their own right and that if specifically managed might lead to better outcomes. The disparity between patients' perceptions and guideline assessment of control may be due to partially controlled asthma being associated with near-maximal levels of quality of life, with minimal impairment. Finally, it is widely assumed that asthma symptom control equates to elimination of risk of asthma attacks, an assumption that may not apply to many patients, particularly those with more severe asthma. We propose that further research be undertaken to determine the optimal levels of asthma control and the potential value of different treatment targets, such as control of type-2 airway inflammation, that can be achieved with currently available treatment, based on efficacy, side effects, and cost.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Beasley R, Braithwaite I, Semprini A, et al. Optimal Asthma Control: Time for a New Target. Am J Respir Crit Care Med. 2020. PMID: 31905013. doi:10.1164/rccm.201910-1934CI

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。